Recent Updates
Recently added Catalysts
VKTX Positive Sentiment

Karen Modesto, MD

Key Takeaway: Dr. Karen Modesto has been appointed as VP of Clinical Development at Viking. With over 25 years of experience in clinical research, she has worked at renowned institutions and has extensive expertise in overseeing clinical trials. Her primary research focus includes cardiovascular and metabolic disorders, enhancing Viking's capabilities in these areas.
Price reaction · baseline $32.1523 (2026-01-09T16:32:00.000Z) · hit during market hours · 3 other VKTX headline(s) in the window, move may be shared
day 0 close · peak
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Modesto has over 25 years of clinical research experience.
  • She has worked in prestigious institutions like Mayo Clinic and Yale.
  • Her expertise includes overseeing clinical trials and ensuring participant safety.
  • She has a strong focus on cardiovascular and metabolic disorders.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
13.6%
average across 5 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
VK2735
Phase 3 · Weight Loss

Full Press Release Details

Dr. Modesto serves as our VP of Clinical Development. She is Board-certified in Cardiology and Echocardiography with over 25 years of clinical research experience. Prior to joining Viking, Dr. Modesto worked for 6 years in academic settings including the Mayo Clinic, Mount Sinai Hospital and Yale School of Medicine. For 13 years, Dr Modesto has worked as a senior medical director for Contract Research Organizations (CROs) such as Worldwide Clinical Trials, ICON and IQVIA overseeing the medical and safety aspects of clinical trials, ensuring participant safety and data integrity in accordance with clinical protocols, SOPs, GCP, regulatory requirements and Sponsor directives. For the past 6 years, she has worked as a senior and executive medical director in Clinical Development in biotechnology companies including Arrowhead Pharmaceuticals with focus in Metabolic disorders, designing, planning and providing medical oversight of clinical studies across all phases of development, overseeing the interpretation and dissemination of study results, including clinical study reports and publications, ensuring alignment with corporate objectives and portfolio priorities. With a broad range of therapeutic indication experience, Dr. Modesto main area of research focus is cardiovascular and metabolic disorders, including diabetes, hyperlipidemia and obesity. Dr Modesto holds an M.D from Universidade Gama Filho, Rio de Janeiro, Brazil.

Frequently Asked Questions

What is Dr. Modesto's role at Viking?

Dr. Modesto serves as the VP of Clinical Development.

How many years of experience does Dr. Modesto have?

She has over 25 years of clinical research experience.

Where did Dr. Modesto work before joining Viking?

She worked at institutions like Mayo Clinic and Yale School of Medicine.

What are Dr. Modesto's research focuses?

Her main areas of focus are cardiovascular and metabolic disorders.

Last updated: Jan 9, 2026